Algert Global LLC Sells 132,698 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Algert Global LLC reduced its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 73.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 46,787 shares of the company's stock after selling 132,698 shares during the period. Algert Global LLC's holdings in Hims & Hers Health were worth $862,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of HIMS. Nisa Investment Advisors LLC boosted its holdings in shares of Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock valued at $37,000 after buying an additional 1,603 shares in the last quarter. Quest Partners LLC boosted its holdings in shares of Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company's stock valued at $72,000 after buying an additional 3,507 shares in the last quarter. CWM LLC boosted its holdings in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company's stock valued at $110,000 after buying an additional 1,054 shares in the last quarter. Van ECK Associates Corp bought a new stake in shares of Hims & Hers Health in the 2nd quarter valued at about $111,000. Finally, Amalgamated Bank boosted its holdings in shares of Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company's stock valued at $133,000 after buying an additional 2,354 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

HIMS has been the topic of a number of recent analyst reports. TD Cowen restated a "buy" rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Bank of America lowered shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and cut their price target for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Imperial Capital downgraded shares of Hims & Hers Health from an "outperform" rating to an "in-line" rating in a research note on Friday, August 9th. Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Finally, Piper Sandler reiterated a "neutral" rating and set a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of "Hold" and an average price target of $20.71.

Hims & Hers Health Price Performance

HIMS stock traded up $1.88 during mid-day trading on Friday, reaching $32.22. 10,258,617 shares of the company's stock were exchanged, compared to its average volume of 9,809,085. The stock's 50 day moving average is $22.01 and its 200 day moving average is $19.86. Hims & Hers Health, Inc. has a 12-month low of $8.09 and a 12-month high of $35.02. The company has a market cap of $7.04 billion, a price-to-earnings ratio of 73.23 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same period in the previous year, the company earned ($0.04) earnings per share. Hims & Hers Health's quarterly revenue was up 77.1% on a year-over-year basis. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, Director Anja Manuel purchased 4,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were acquired at an average cost of $26.94 per share, for a total transaction of $107,760.00. Following the acquisition, the director now directly owns 4,000 shares in the company, valued at approximately $107,760. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the company's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the sale, the chief executive officer now owns 33,502 shares of the company's stock, valued at $487,789.12. This represents a 84.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,153,519 shares of company stock worth $24,486,721. Company insiders own 17.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.